Vista Investment Partners II LLC Has $2.21 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Vista Investment Partners II LLC lifted its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 16.3% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,409 shares of the company's stock after buying an additional 1,878 shares during the period. Vista Investment Partners II LLC's holdings in Zoetis were worth $2,208,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Rakuten Securities Inc. raised its position in shares of Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after purchasing an additional 166 shares during the period. Navigoe LLC acquired a new stake in shares of Zoetis during the fourth quarter worth $30,000. Murphy & Mullick Capital Management Corp acquired a new stake in shares of Zoetis during the fourth quarter worth $44,000. Sound Income Strategies LLC raised its position in shares of Zoetis by 141.4% during the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock worth $46,000 after purchasing an additional 164 shares during the period. Finally, Bfsg LLC raised its position in shares of Zoetis by 614.6% during the first quarter. Bfsg LLC now owns 293 shares of the company's stock worth $48,000 after purchasing an additional 252 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. UBS Group cut their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Wall Street Zen raised Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Piper Sandler upped their price target on Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Monday, May 12th. Finally, Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and dropped their price target for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $212.13.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of the company's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the sale, the executive vice president now owns 15,129 shares in the company, valued at approximately $2,571,930. This represents a 4.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.18% of the stock is currently owned by corporate insiders.

Zoetis Stock Up 0.2%

NYSE ZTS traded up $0.38 on Friday, reaching $156.17. The stock had a trading volume of 2,987,838 shares, compared to its average volume of 2,566,643. The business has a 50 day moving average price of $160.40 and a 200 day moving average price of $162.73. The company has a current ratio of 1.74, a quick ratio of 1.04 and a debt-to-equity ratio of 1.12. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The company has a market capitalization of $69.53 billion, a price-to-earnings ratio of 28.04, a P/E/G ratio of 2.58 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The firm had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The business's quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.38 earnings per share. On average, analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 annualized dividend and a dividend yield of 1.28%. Zoetis's dividend payout ratio (DPR) is presently 35.91%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.